Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin

Yi-Hong Zeng, Sung-Chen Liu, Chun-Chuan Lee, Fang-Ju Sun, Jason J Liu, Yi-Hong Zeng, Sung-Chen Liu, Chun-Chuan Lee, Fang-Ju Sun, Jason J Liu

Abstract

Insulin therapy often increases body weight and leads to visceral fat accumulation. Progression in diabetes is also associated with accelerated loss of muscle mass. Little is known about body composition changes in type 2 diabetes mellitus (T2DM) patients on insulin therapy who use sodium-glucose cotransporter-2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors. This study examined the effect of 25 mg of empagliflozin compared with 5 mg of linagliptin for 24 weeks on body weight and body composition in patients with T2DM on premixed insulin. Body composition was assessed with bioelectrical impedance analysis. The mean difference between the linagliptin and empagliflozin groups in terms of mean body weight change from baseline to 24 weeks was - 1.80 kg (95% CI - 2.57, - 1.03). Empagliflozin also significantly reduced muscle mass (- 1.39 kg, 95% CI - 2.49, - 0.29) and total body water (- 1.07 kg, 95% CI - 1.88, - 0.27) compared with linagliptin. Compared to linagliptin, empagliflozin decreased body fat mass more from baseline to week 24, but this was not significant (- 0.31 kg, 95% CI - 1.51, 0.90). Further research on insulin-treated T2DM patients is necessary to investigate the long-term effects of SGLT2 and DPP4 inhibitors on body composition, as well as their effects on muscle strength and physical function.Trial registration: ClinicalTrials.gov no. NCT03458715, registration date: March 8, 2018.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

References

    1. Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: Treating "sick fat" through improving fat function with antidiabetes therapies. Am. J. Cardiol. 2012;110:4B–12B. doi: 10.1016/j.amjcard.2012.08.029.
    1. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc. Res. 2007;75:690–701. doi: 10.1016/j.cardiores.2007.03.008.
    1. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2:819–829. doi: 10.1016/s2213-8587(14)70034-8.
    1. Tang H, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 2017;19:142–147. doi: 10.1111/dom.12785.
    1. Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 2012;97:1020–1031. doi: 10.1210/jc.2011-2260.
    1. Inoue H, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. J. Diabetes Investig. 2019;10:1012–1021. doi: 10.1111/jdi.12985.
    1. Frandsen CS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: A review. Diabet. Med. 2014;31:1293–1300. doi: 10.1111/dme.12561.
    1. Kato H, et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015;109:199–205. doi: 10.1016/j.diabres.2015.04.008.
    1. Bouchi R, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 2018 doi: 10.1002/dmrr.2957.
    1. Liu SC, Lee CC, Chuang SM, Sun FJ, Zeng YH. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study. Diabetes Metab. 2020 doi: 10.1016/j.diabet.2020.08.001.
    1. Berker D, et al. Compatibility of different methods for the measurement of visceral fat in different body mass index strata. Diagn. Interv. Radiol. 2010;16:99–105. doi: 10.4261/1305-3825.DIR.2749-09.1.
    1. Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study. J. Diabetes Investig. 2019;10:108–117. doi: 10.1111/jdi.12851.
    1. Schork A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy. Cardiovasc. Diabetol. 2019;18:46. doi: 10.1186/s12933-019-0852-y.
    1. Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte. 2018;7:121–128. doi: 10.1080/21623945.2017.1413516.
    1. Shaheer A, Kumar A, Menon P, Jallo M, Basha S. Effect of add-on therapy of dapagliflozin and empagliflozin on adipokines in Type 2 diabetes mellitus. J. Endocrinol. Metab. 2021;11:83–90. doi: 10.14740/jem751.
    1. Sakurai S, et al. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis. J. Diabetes Complicat. 2020;34:107703. doi: 10.1016/j.jdiacomp.2020.107703.
    1. Rizzo MR, et al. Sarcopenia in elderly diabetic patients: Role of dipeptidyl peptidase 4 inhibitors. J. Am. Med. Dir. Assoc. 2016;17:896–901. doi: 10.1016/j.jamda.2016.04.016.
    1. Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: Considerations for their appropriate use to avoid serious adverse events. Expert Opin. Drug Saf. 2015;14:795–800. doi: 10.1517/14740338.2015.1034105.
    1. Qin Q, et al. Bioelectrical impedance analysis versus quantitative computer tomography and anthropometry for the assessment of body composition parameters in China. Sci. Rep. 2021;11:11076. doi: 10.1038/s41598-021-90641-5.
    1. Roubenoff R. Sarcopenia: Effects on body composition and function. J. Gerontol. A Biol. Sci. Med. Sci. 2003;58:1012–1017. doi: 10.1093/gerona/58.11.m1012.
    1. Jensen B, et al. Ethnic differences in fat and muscle mass and their implication for interpretation of bioelectrical impedance vector analysis. Appl. Physiol. Nutr. Metab. 2019;44:619–626. doi: 10.1139/apnm-2018-0276.
    1. Gan S, et al. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2020;43:1948–1957. doi: 10.2337/dc19-2419.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner